

ABSTRACT

RISK FACTORS OF ANTI-TUBERCULOSIS DRUGS-INDUCED HEPATOTOXICITY IN CENTRAL CHEST INSTITUTE OF THAILAND

SIRIJIT RATTANAWAI : CENTRAL CHEST INSTITUTE OF THAILAND

The purpose of this descriptive statistic research was to determine the rate and risk factors of drug-induced hepatotoxicity in tuberculosis patients treatment at Central Chest Institute of Thailand. The study was three-years retrospective, collected data from the patient charts between January 1st 2008 and December 31st 2010. Two hundred and twenty seven patients were selected from four hundred and forty seven drug-induced hepatotoxic tuberculosis patients based on the inclusion criteria, calculated as 50.78%. The percentage of tuberculosis patients in Central Chest Institute of Thailand (3,482) having drug-induced hepatotoxicity was 6.52.

The result shown that the mean \pm SD onset of hepatotoxicity in patients who received H300:R600:Z1500:E1000 regimen was higher than the patient who received H300:R450:Z1000:E800 regimen. Relate to the patient's weight, there is a greater risk of hepatotoxicity in patients with less than 45 kilograms for 1.49 fold significantly (OR = 1.49 (95%CI : 1.14 – 1.95, P = 0.0037). According to the research, patient,s weight is the second risk of hepatotoxicity. And the gender was found to be associated with hepatotoxicity from anti-tuberculosis drugs cause the research found that male has more than female, for 1.73 fold.(OR = 1.73 (95%CI : 1.32 – 2.27, Z statistic = 3.930, P = 0.001)

Reference

[1] World Health Organization. Global Tuberculosis Control 2008 Surveillance Planning Financing : WHO report 2008 . Geneva: World Health Organization, 2008.

[2] Jittimane S, Vorasingha J, Mad-asin W, Nateniyom S, Rienthong S, and Varma J.K. Tuberculosis in Thailand: epidemiology and program performance, 2001-2005. Int J Inf Dis. 2009;13:436-42.

[3] Yew WW, and Leung CC. Antituberculosis drugs and hepatotoxicity. Respirology. 2006; 14:699-707.

เสนอโดยนางสาวสิริจิต รัตนวัย เภสัชกรชำนาญการพิเศษ สถาบันโรคทรวงอก

ในการประชุม 25th FAPA Congress 2014

ซึ่งจัดขึ้นระหว่างวันที่ 9 - 11 ตุลาคม 2557 ณ ประเทศมาเลเซีย

[4] Yee D, Valiquette C, Pellertier M, Parisien I, Rocher I, and Menzies D. Incidence of Serious Side Effects from First-line Antituberculosis Drugs among Patients Treated for Active Tuberculosis. *Am J Respir Crit Care Med.* 2003; 167:1472-7.

[5] Thompson N.P, Caplin M.E, Hamilton M.I, Gillespie S.H, Clarke S.W, Burroughs A.K, et al. Anti-tuberculosis medication and the liver: dangers and recommendations in management. *Eur Respir J.* 1995; 8:1384-8.

[6] Ungo J.R, Jones D, Ashkin D, Hollender E.S, Bernstein D, Albanese A.P, et al. Antituberculosis Drug-induced Hepatotoxicity: The Role of hepatitis C Virus and the Human Immunodeficiency Virus. *Am J Respir Crit Care Med.* 1998;157:1871-6.

[7] Wai T.C. Presentation of drug-induced liver injury in Singapore. *Singapore Med J.* 2006;47(2):116-120.

[8] Anand A.C, Seth A.K, Paul M, and Puri P. Risk Factors of Hepatotoxicity During Anti-tuberculosis Treatment. *MJAFI.* 2006;62(1): 45-49.

[9] Krittiyanunt S, Sakulbamrungsil R, Wongwiwatthanakit S, and Suthiputthanangoon W. Risk Factors of Antituberculosis Drugs-Induced Hepatotoxicity in Thai Patients. *Thai J Pharm Sci.* 2002; 26(3-4):121-8.

[10] Ward F. and Daly M. Hepatic disorder. In Lee A. (ed.), *Adverse drug reactions*, pp 78-95. London: Pharmaceutical Press, 2001.

[11] Nolan C.M., Goldberg S.V. and Buskin S.E. Hepatotoxicity associated with isoniazid preventive therapy: A 7 years survey from a Public Health Tuberculosis Clinic. *JAMA.* 1999;281(11):1014-8.

[12] Lorent N, Sebatunzi O, Mukeshimana G, Van den Ende J, and Clerinx J. Incidence and risk factors of serious adverse events during antituberculous treatment in Rwanda: a prospective cohort study. *PLoS One.* 2011;6(5):e19566. Epub 2011 May 18.

[13] Lanternier F, Dalban C, Perez L, Bricaire F, Costagliola D and Caumes E. Tolerability of anti-tuberculosis treatment and HIV serostatus. *Int J Tuberc Lung Dis.* 2007 Nov;11(11):1203-9.

[14] Anand A.C, Seth A.K, Paul M, and Puri P. Risk Factors of Hepatotoxicity During Anti-tuberculosis Treatment. *MJAFI.* 2006;62(1): 45-49.